viewPreveCeutical Medical Inc.

PreveCeutical says cannabinoid Sol-gel formulations showed physical and chemical stability in study

The formulations’ components underwent three months of cold storage as well as room temperature storage 

PreveCeutical Medical Inc. - PreveCeutical Medical Inc announces successful results from its cannabinoid Sol-gel product development program
PreveCeutical said it will conduct a further stability study program

PreveCeutical Medical Inc (CSE:PREV) (OTCQB:PRVCF) announced Monday successful results from its cannabinoid Sol-gel product development program.

The Vancouver-based company said the results came from a three-month physico-chemical stability test on cannabinoid sol-gel formulations designed for nose-to-brain (NTB) delivery.

PreveCeutical said it looked at the physical and chemical stability of formulations’ components, which underwent three months of cold storage (2-8ºC) as well as room temperature storage. 

READ: PreveCeutical executes pact for developing CBD Sol-Gel nasal spray formulation as a potential coronavirus treatment

As a result, “there was minimal indication of physical or chemical instability of the cannabinoid formulation over the study period,” the company said in a statement. 

Quality evaluation testing of cannabis extracts was conducted using high-performance liquid chromatography (HPLC) and liquid chromatography-mass spectrometry (LC-MS) profiles to generate chemical fingerprints that were later qualified, validated and verified using analytical grade cannabinoid standards, it added. 

Based on the before and after HPLC testing, the company said the study found that the cannabinoid content within the formulation generally remained within the study's acceptance criteria.

PreveCeutical said it will conduct a further stability study program as and when required by the regulatory authorities, and in accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.

With the use of an applicator, the sustained-released Sol-gel formulations allow for the direct and prolonged delivery of cannabinoids to a patient's central nervous system. 

PreveCeutical and its Australian partner are now developing a Sol-gel CBD formula that could fight off the ability of SARS-CoV-2, the virus that causes the coronavirus (COVID-19) disease, to infect nasal tissue.

"We are very pleased with these results. With the increasing evidence of the clinical benefit of cannabinoids, our cannabinoid sol-gel solution aims to meet our study target,” said CEO Stephen Van Deventer. “We plan to protect this IP and will be looking to work with a suitable partner and progressing through preclinical to clinical study development."

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Quick facts: PreveCeutical Medical Inc.


Price: 0.03 CAD

Market Cap: $15.35 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


PreveCeutical Medical announces completion on analgesic program is near

PreveCeutical Medical (CSE:PREV-OTCQB: PRVCF) CEO Stephen Van Deventer joined Steve Darling from Proactive Vancouver with news the company’s current stage of research for its disulfide linker technology will be completed soon. Van Deventer telling Proactive about the program and what the next...

on 23/7/20

2 min read